Total Payments
$1.2M
2024 Payments
$142,727
Companies
30
Transactions
1,074
Medicare Patients
1,915
Medicare Billing
$214,486
Payment Breakdown by Category
Other$763,906 (63.8%)
Consulting$270,222 (22.6%)
Research$90,577 (7.6%)
Travel$52,472 (4.4%)
Food & Beverage$19,633 (1.6%)
Education$343.60 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $761,106 | 309 | 63.6% |
| Consulting Fee | $270,222 | 89 | 22.6% |
| Unspecified | $90,577 | 23 | 7.6% |
| Travel and Lodging | $52,472 | 210 | 4.4% |
| Food and Beverage | $19,633 | 432 | 1.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,800 | 1 | 0.2% |
| Education | $343.60 | 10 | 0.0% |
Payments by Type
General
$1.1M
1,051 transactions
Research
$90,577
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $244,941 | 253 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $198,260 | 166 | $0 (2020) |
| ABBVIE INC. | $166,440 | 147 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $103,750 | 82 | $0 (2022) |
| Eli Lilly and Company | $96,860 | 23 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $90,186 | 71 | $0 (2024) |
| UCB, Inc. | $65,948 | 49 | $0 (2024) |
| Janssen Biotech, Inc. | $61,677 | 99 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $32,095 | 37 | $0 (2021) |
| GENZYME CORPORATION | $26,850 | 13 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $142,727 | 119 | UCB, Inc. ($53,669) |
| 2023 | $170,646 | 121 | E.R. Squibb & Sons, L.L.C. ($42,951) |
| 2022 | $104,605 | 92 | Lilly USA, LLC ($32,450) |
| 2021 | $56,484 | 37 | Janssen Scientific Affairs, LLC ($15,959) |
| 2020 | $106,088 | 67 | AbbVie Inc. ($25,644) |
| 2019 | $240,130 | 230 | Eli Lilly and Company ($61,612) |
| 2018 | $189,800 | 202 | Novartis Pharmaceuticals Corporation ($62,128) |
| 2017 | $186,673 | 206 | Novartis Pharmaceuticals Corporation ($60,857) |
All Payment Transactions
1,074 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $99.04 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 11/27/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
| 11/22/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,075.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | Cash or cash equivalent | $33.50 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | Cash or cash equivalent | $25.63 | General |
| Category: Immunology | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $13.40 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | Cash or cash equivalent | $11.46 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | Cash or cash equivalent | $10.02 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,300.00 | General |
| Category: Immunology | ||||||
| 11/07/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Immunology | ||||||
| 11/06/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: Immunology | ||||||
| 11/02/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $57.93 | General |
| Category: Immunology | ||||||
| 11/02/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $38.73 | General |
| Category: Immunology | ||||||
| 11/02/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $38.30 | General |
| Category: Immunology | ||||||
| 11/01/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $351.01 | General |
| Category: Immunology | ||||||
| 11/01/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $298.64 | General |
| Category: Immunology | ||||||
| 10/30/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,000.00 | General |
| Category: Immunology | ||||||
| 10/23/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/23/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
| 10/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $27,228 | 4 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $22,972 | 1 |
| PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED SINGLE-ARM PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB | Eli Lilly and Company | $19,482 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | Eli Lilly and Company | $7,876 | 3 |
| A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $3,984 | 3 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | Eli Lilly and Company | $2,651 | 3 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $1,768 | 1 |
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects with Active Psoriatic Arthritis (CC-10004-PSA-002) | Celgene Corporation | $1,144 | 1 |
| A Phase 4, Multicenter, Randomized, Placebo-controlled, Double-blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate Plaque Psoriasis (CC-10004-PSOR-012) | Celgene Corporation | $1,144 | 1 |
| CC-10004-PSA-002 - A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects with Active Psoriatic Arthritis | Celgene Corporation | $1,082 | 1 |
| CC-10004-PSOR-012 - A Phase 4, Multicenter, Randomized, Placebo-controlled, Double-blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate Plaque Psoriasis | Celgene Corporation | $442.00 | 1 |
| CC-10004-PSA-002 | Celgene Corporation | $417.00 | 1 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $282.38 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 443 | 809 | $139,026 | $47,910 |
| 2022 | 9 | 526 | 903 | $160,111 | $58,617 |
| 2021 | 10 | 492 | 942 | $159,889 | $63,216 |
| 2020 | 10 | 454 | 893 | $138,115 | $44,744 |
Total Patients
1,915
Total Services
3,547
Medicare Billing
$214,486
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 148 | 213 | $29,820 | $12,836 | 43.0% |
| 88350 | Antibody evaluation, each additional single antibody stain procedure | Office | 2023 | 32 | 144 | $24,480 | $12,502 | 51.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 75 | 102 | $20,808 | $8,691 | 41.8% |
| 88346 | Antibody evaluation, initial single antibody stain procedure | Office | 2023 | 29 | 35 | $8,610 | $3,760 | 43.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $9,180 | $2,947 | 32.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 47 | 58 | $21,634 | $2,338 | 10.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 28 | 28 | $6,720 | $2,027 | 30.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 23 | 28 | $10,640 | $1,974 | 18.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 34 | 174 | $7,134 | $833.67 | 11.7% |
| 88350 | Antibody evaluation, each additional single antibody stain procedure | Office | 2022 | 44 | 183 | $31,110 | $16,014 | 51.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 157 | 233 | $32,620 | $14,124 | 43.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 109 | 147 | $29,988 | $12,428 | 41.4% |
| 88346 | Antibody evaluation, initial single antibody stain procedure | Office | 2022 | 43 | 47 | $11,562 | $5,330 | 46.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 38 | 38 | $12,920 | $3,945 | 30.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 37 | 37 | $8,880 | $2,364 | 26.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 26 | 27 | $10,260 | $1,888 | 18.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 43 | 45 | $16,785 | $1,781 | 10.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 29 | 146 | $5,986 | $742.36 | 12.4% |
| 88350 | Antibody evaluation, each additional single antibody stain procedure | Office | 2021 | 58 | 249 | $41,820 | $20,749 | 49.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 152 | 247 | $34,580 | $15,142 | 43.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 92 | 133 | $27,132 | $11,659 | 43.0% |
| 88346 | Antibody evaluation, initial single antibody stain procedure | Office | 2021 | 53 | 61 | $14,760 | $6,578 | 44.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 22 | 22 | $7,480 | $2,682 | 35.9% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 30 | 30 | $7,200 | $2,379 | 33.0% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 18 | 20 | $7,600 | $1,396 | 18.4% |
About Dr. Neil Korman, MD
Dr. Neil Korman, MD is a Dermatology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1326067778.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Neil Korman, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $142,727 received in 2024. These payments were reported across 1,074 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($761,106).
As a Medicare-enrolled provider, Korman has provided services to 1,915 Medicare beneficiaries, totaling 3,547 services with total Medicare billing of $214,486. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties Clinical & Laboratory Dermatological Immunology
- Location Cleveland, OH
- Active Since 07/18/2006
- Last Updated 01/05/2021
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1326067778
Products in Payments
- TALTZ (Drug) $212,166
- COSENTYX (Biological) $188,888
- TREMFYA (Drug) $81,968
- SKYRIZI (Biological) $61,756
- Sotyktu (Drug) $59,941
- Bimzelx (Biological) $57,519
- Tremfya (Drug) $51,316
- RINVOQ (Biological) $43,991
- DUPIXENT (Biological) $29,781
- Humira (Biological) $27,324
- Skyrizi (Biological) $24,685
- OLUMIANT (Drug) $22,575
- STELARA (Biological) $18,012
- Otezla (Drug) $17,337
- DUPIXENT DUPILUMAB INJECTION (Biological) $16,798
- Olumiant (Drug) $14,481
- SPEVIGO (Drug) $13,296
- DUPIXENT (Drug) $12,366
- Rituxan (Biological) $9,070
- XELJANZ (Drug) $7,745
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Cleveland
Dr. Shilpi Khetarpal, Md, MD
Dermatology — Payments: $351,386
Dermatology $351,386
Alex Hirsh, M.d, M.D
Dermatology — Payments: $164,842
Dermatology $164,842
Samantha Polly, Md, MD
Dermatology — Payments: $80,467
Dermatology $80,467
Wilma Bergfeld, M.d, M.D
Dermatology — Payments: $37,206
Dermatology $37,206
David Hamrock, M.d, M.D
Dermatology — Payments: $21,867
Dermatology $21,867
Dr. Mara Weinstein Velez, M.d, M.D
Dermatology — Payments: $18,076
Dermatology $18,076